CD99 CLEC12A: Novel Bispecific CD99 CLEC12A scFv CAR-T Cells for Acute Myeloid Leukemia Immunotherapy

FOR MORE INFORMATION ON THIS TECHNOLOGY, PLEASE CONTACT OUR OFFICE

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596

17MB042T2N